
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
The development of a successful powder for injection formulation requires careful study of preformulation parameters, packaging and process parameters, and the elimination of particulate matter.
over 24 years ago
Outsourcing Outlookover 24 years ago
Developing Custom Adhesive Systems for Transdermal Drug Deliveryover 24 years ago
PDA Task Force Issues Guidelines to Aid Isolator Usersover 24 years ago
Drug Safety Concerns Shape Manufacturing Policyover 24 years ago
Production Information Mangementover 24 years ago
Validation Changes to the USP Assay Method for Ibuprofen Tablets